In May 2010 the WIPO Secretariat published a paper entitled “WIPO Scoping Study on Copyright and Related Rights and the Public Domain” prepared by Professor Séverine Dusollier (Professor, University of Namur, Belgium). This study was produced as an output of the WIPO Committee on Development and Intellectual Property’s (CDIP) thematic project on intellectual property and the public domain which is predicated upon Recommendations 16 and 20 of the Development Agenda.
Continue Reading →
KEI has obtained a copy of the August 25, 2010 version of the ACTA consolidated negotiating text. This is Part 1 of our initial notes on the document.
(Part 2 is available here.)
(revised September 9, 2010)
Preamble
The preamble in the August, 25, 2010 text includes 10 paragraphs, of which only 3 do not have brackets.
Continue Reading →
101st Session
EB101.R24
Agenda item 9
27 January 1998
Revised drug strategy
The Executive Board
RECOMMENDS to the Fifty-first World Health Assembly the adoption of the following resolution:
The Fifty-first World Health Assembly,
Recalling resolutions WHA39.27, WHA41.16, WHA43.20, WHA45.27, WHA47.12, WHA47.13, WHA47.16, WHA47.17, and WHA49.14;
Having considered the report of the Director-General on the revised drug strategy[1];
Continue Reading →
A pdf copy of the resolution is attached to this page.
THE FIFTY-SECOND WORLD HEALTH ASSEMBLY
WHA52.19
Agenda Item 13
May 24, 1999
Revised Drug Strategy
The Fifty-second World Health Assembly,
Recalling resolution WHA39.27, WHA41.16, WHA43.20, WHA45.27, WHA47.12, WHA47.13, WHA47.16, WHA47.17, and WHA49.14;
Having considered the report of the Director-General on the revised drug strategy[1];
Continue Reading →
CONFIDENTIAL RELEASED IN FULL
CONFIDENTIAL PTQ1906
PAGE 01 GENEVA 03470 01 OF 09 271621Z ACTION 10-00
425261 271705Z /38 O 271615Z MAY 98
FM USMISSION GENEVA
TO SECSTATE WASHDC IMMEDIATE 6208 INFO IO COLLECTIVE AMEMBASSY LONDON
AMEMBASSY BRASILIA
AMEMBASSY BUENOS AIRES AMEMBASSY PRETORIA AMEMBASSY HARARE
AMEMBASSY LILONGWE AMEMBASSY LUSAKA
AMEMBASSY WINDHOEK AMEMBASSY BERN
AMEMBASSY CANBERRA
AMEMBASSY STOCKHOLM AMEMBASSY TOKYO AMEMBASSY OSLO
AMEMBASSY BRUSSELS AMEMBASSY BONN
AMEMBASSY OTTAWA AMEMBASSY CAIRO CDC ATLANTA
Continue Reading →
Draft
This is work in progress, and is part of a larger project on timelines. This particular timeline is unfinished, and may contain errors.
Timeline of privileged regarding the commercialization and use of knowledge
Continue Reading →
On Tuesday, August 17, 2010, USTR organized a lunch between ACTA negotiators and civil society NGOs. There was not much notice. We received our invite to the lunch last Thursday. Representatives from KEI, Public Citizen, Oxfam, Public Knowledge and the American University program on intellectual property attended the event.
Continue Reading →
Background
Beginning in 1985, the United States government (USG) diplomatic and trade officials have engaged in wide ranging activities aimed at changing global norms for the protection of intellectual property rights, with a particular emphasis on the IPR protections for pharmaceutical products.
This note reports on U.S. Department of State cables sent in 1986 and 1987, that discussed the U.S. government efforts to change policies in Brazil on the intellectual property protection for pharmaceutical products. The cables have been obtained by KEI with a FOIA request.
Continue Reading →
Prices for Abbott’s Norvir (generic name Ritonavir) as a Standalone Product in 2010 KEI Research Note 2010:4 August 12, 2010 Anne Mira Guha Prices for Abbott’s Norvir (generic name Ritonavir) as a Standalone Product in 2010 1. Introduction Ritonavir is… Continue Reading →
From the FDA page on the Orphan Drug Tax Credit. Incentives TAX CREDIT (See Footnote 1 below) FOR TESTING EXPENSES FOR DRUGS FOR RARE DISEASES OR CONDITIONS Introduction Section 45C of the Internal Revenue Code of 1954 allows a credit… Continue Reading →